AGC Biologics has joined the Orphan Therapeutics Accelerator's (OTXL) clinical development network as a dedicated manufacturing partner, adding ex vivo lentiviral vector gene therapy production capacity to a non-profit model designed to revive shelved ultra-rare disease programs. The partnership formalizes and expands a relationship that began through AGC's work as manufacturer for Fondazione Telethon's Waskyra (etuvetidigene autotemcel), the gene therapy that received US FDA approval in December 2025. AGC Biologics is a subsidiary of AGC Inc. (Tokyo Stock Exchange: 5201), a Japanese conglomerate whose life science division operates more than ten facilities globally. Financial terms were not disclosed.
Deal context
OTXL, a Cambridge, Massachusetts-based non-profit, operates through a model in which it acquires clinical-stage programs that have been abandoned for commercial rather than scientific reasons, then routes them through its Orphan ClinDevNet — a pre-assembled network of contract development and manufacturing organizations, CROs, and other partners — to complete development at deferred or reduced cost. When an approved program generates revenue, net proceeds are used to repay network partners, with a portion returned to OTXL to fund additional programs. AGC Biologics' entry into that network as a manufacturing partner extends the platform's end-to-end capability for programs relying on autologous cell and gene therapy manufacturing.
The manufacturing approach at the center of the collaboration is ex vivo lentiviral vector-mediated transduction of autologous CD34+ hematopoietic stem and progenitor cells. In this process, a patient's own stem cells are harvested, genetically modified outside the body using a lentiviral vector that stably integrates a therapeutic gene into the cell genome, and reinfused following myeloablative conditioning. The approach is well-characterized in the published literature for monogenic blood and immune disorders, and AGC Biologics' Milan facility has been the manufacturing site for multiple programs reaching commercial approval, including Lenmeldy (atidarsagene autotemcel) for metachromatic leukodystrophy, which received US FDA approval in March 2024.
The Milan site carries regulatory clearance from the US FDA, the European Medicines Agency, and the UK Medicines and Healthcare products Regulatory Agency, and the company reports eleven viral vector and seven cell therapy commercial approvals supported from that facility.
Waskyra, the immediate anchor program for the OTXL relationship, was the first gene therapy to receive US FDA approval by a non-profit organization. OTXL's subsidiary Orphan Therapies serves as its US commercialization partner, while AGC Biologics continues as manufacturer, giving the two organizations an established operational relationship on which the broader network agreement is built.